Results 1 to 10 of about 29,569 (118)

Myeloid/Lymphoid Neoplasm with FGFR1::ZMYM2 Rearrangement Presenting as T-Cell Acute Lymphoblastic Lymphoma with Concurrent Myeloproliferative Neoplasm: A Case Report [PDF]

Hematology Reports
Background: Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN-FGFR1), also known as 8p11 myeloproliferative syndrome, are rare and aggressive hematologic malignancies arising from pluripotent stem cells.
Meha Krishnareddigari, Gopal Patel, Aqiba Bokhari, John Paul Graff, Denis M. Dwyre, Arun Panigrahi   +5 more
doaj   +2 more sources

The molecular management of classic myeloproliferative neoplasm [PDF]

Journal of the Egyptian National Cancer Institute
Background Whole-genome sequencing has enabled the development of a wide range of analytical tools to search for abnormalities associated with tumors. As classic myeloproliferative neoplasms (MPNs) are associated with genomic alterations in hematopoietic
Charlène G. S. Soro, Sara Benchikh, Adil El Hamouchi, Imane Morjane, Rachid Saile, Halima Lebrazi, Sanaa Nassereddine   +6 more
doaj   +2 more sources

Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study

EClinicalMedicine, 2020
Background: Whether inflammation is independently associated with development of JAK2V617F mutation and myeloproliferative neoplasm is not clear. We tested the hypothesis that a loss-of-function polymorphism in IL6R (marked by rs4537545) reduces risk of ...
Kasper Mønsted Pedersen, Yunus Çolak, Christina Ellervik, Hans Carl Hasselbalch, Stig Egil Bojesen, Børge Grønne Nordestgaard   +5 more
doaj   +1 more source

Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study

EClinicalMedicine, 2020
Background: High cardiovascular comorbidity contributes to excess mortality in patients with myeloproliferative neoplasm, while less is known about respiratory comorbidity and mortality.
Kasper Mønsted Pedersen, Yunus Çolak, Hans Carl Hasselbalch, Christina Ellervik, Børge Grønne Nordestgaard, Stig Egil Bojesen   +5 more
doaj   +1 more source

Granulocytic sarcoma: Extramedullary manifestation of chronic myeloproliferative neoplasm in a young African woman

Human Pathology: Case Reports, 2021
We present a rare case of multiple granulocytic sarcoma in a young African woman in blast phase of chronic myeloproliferative neoplasm. Fine needle aspiration cytology of the sarcoma, peripheral blood film and bone marrow aspiration cytology were ...
Ajayi A. Ibijola, Abiodun I. Okunlola, Abiodun O. Awe   +2 more
doaj   +1 more source

Severe Dizziness and Hypereosinophilia: Coincidence or Complication? A Case Report

Case Reports in Oncology, 2020
Hypereosinophilia is a common issue in medicine. One rare cause is myeloproliferative neoplasm with PDGFRA rearrangement. In these patients, the gold standard for therapy is low-dose imatinib.
Giorgia Lo Presti, Beatrice Barda, Mario Uhr, Monika Raimondi, Oreste Mora   +4 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms

eJHaem, 2022
This report highlights the value of flow cytometry analysis, particularly in the setting of myeloproliferative neoplasms showing features of progression, as neoplastic plasmacytoid dendritic cell (PDC) proliferations may be present, representing either a
Siba El Hussein, Mariko Yabe, Wei Wang, Naveen Pemmaraju, Sanam Loghavi, Fatima Zahra Jelloul, Hong Fang, L. Jeffrey Medeiros, W. Richard Burack, Andrew G. Evans, Jane L. Liesveld, John M. Bennett   +11 more
doaj   +1 more source

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values

Haematologica, 2019
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV),
Richard T. Silver, Spencer Krichevsky
doaj   +1 more source

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation

SAGE Open Medical Case Reports, 2021
The entity myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome is characterized by the coexistence of both myeloproliferative and myelodysplastic features in the bone marrow.
Anette Lodvir Hemsing, Bjørn Tore Gjertsen, Signe Spetalen, Lars Helgeland, Håkon Reikvam   +4 more
doaj   +1 more source

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate

Haematologica, 2014
Clinical significance of the JAK2V617F mutation in patients with a myeloproliferative neoplasm has been the target of intensive research in recent years. However, there is considerably uncertainty about prognosis in JAK2V617F positive individuals without
Camilla Nielsen, Stig E. Bojesen, Børge G. Nordestgaard, Klaus F. Kofoed, Henrik S. Birgens   +4 more
doaj   +1 more source